Abiopharma

🔍 Boucher Kelley (Executive)

Company: Apellis Pharmaceuticals, Inc. (APLS)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Acquired 30,476 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 97,658.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 45,766 shares of Stock Option (Right to Buy) at $28.17 per share (Derivative)
  Date: 2025-09-02 | Code: A | Expires: 2035-09-02 | equity_swap_involved: 0 | shares_owned_after: 45,766.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: This restricted stock unit was granted on September 2, 2025. The restricted stock unit will vest 25% annually over four years from grant date, subject to her continued service as an officer, or upon later termination of her service.
• F2: This represents a stock option award granted September 2, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.